Table 1.
Characteristics of included studies in this meta-analysis.
| Authors(Year) | Level evidence | Group | Number of subjects | Age (year), mean (s.d) | Female (%) | BMI (Kg/m2), mean (s.d) | T-score (lumbar spine), mean (s.d) | T-score (total hip), mean (s.d) | T-score (femoral neck), mean (s.d) | P1NP (μg/L), mean (s.d) | TRACP-5b (mU/dl), mean (s.d) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kobayakawa 2022 | Level III | Denosumab | 36 | 70.0 (11.2) | 31 (86.1) | 21.3 (3.7) | -1.79 (1.42) | -2.33 (0.88) | -2.53 (0.82) | 34.9 (21.0) | 378.2 (225.4) | |
| Romosozumab | 36 | 71.2 (13.3) | 30 (82.9) | 20.4 (3.4) | -1.79 (1.44) | -2.71 (1.08) | -2.39 (1.15) | 44.5 (38.0) | 296.5 (143.6) | |||
| Kobayakawa 2021 | Level III | Denosumab | 69 | 74.20 (11.32) | Not mentioned | 21.15 (3.39) | -2.50 (1.13) | -2.55 (0.73) | -3.12 (0.62) | 59.1 (36.6) | 476.6 (205.2) | |
| Romosozumab | 69 | 75.83 (9.70) | Not mentioned | 22.09 (3.24) | -2.62 (1.25) | -2.57 (0.84) | -3.12 (0.82) | 70.0 (44.3) | 528.4 (255.2) | |||
| Mochizuki 2022 | Level III | Denosumab | 26 | 74.8 (7.9) | Not mentioned | 21.1 (2.6) | -2.1 (1.1) | -2.4 (1.0) | -2.9 (0.7) | 47.6 (29.0) | 455.7 (169.8) | |
| Romosozumab | 25 | 72.0 (7.7) | Not mentioned | 21.7 (3.2) | -1.8 (1.0) | -2.1 (0.5) | -2.6 (0.6) | 35.6 (16.0) | 388.3 (164.7) | |||
| Shimizu 2021 (Vit D) | Level III | Denosumab | 38 | 75.3 (5.4) | Not mentioned | 22.1 (2.6) | Not mentioned | Not mentioned | Not mentioned | 62.7 (26.5) | 497.6 (158.8) | |
| Romosozumab | 43 | 71.8 (6.3) | Not mentioned | 22.7 (2.1) | Not mentioned | Not mentioned | Not mentioned | 56.3 (24.3) | 451.0 (116.1) | |||
| Shimizu 2021 (BPs) | Level III | Denosumab | 35 | 73.7 (7.3) | Not mentioned | 20.0 (2.6) | Not mentioned | Not mentioned | Not mentioned | 30.2 (19.6) | 285.5 (121.6) | |
| Romosozumab | 38 | 74.4 (6.4) | Not mentioned | 22.2 (2.6) | Not mentioned | Not mentioned | Not mentioned | 21.6 (8.5) | 279.5 (86.2) | |||
| Jeong 2021 | Level III | Denosumab | 21 | 66.0 (8.6) | Not mentioned | 22.9 (2.5) | -2.40 (0.73) | Not mentioned | Not mentioned | Not mentioned | Not mentioned | |
| Romosozumab | 10 | 66.8 (8.1) | Not mentioned | 23.1 (3.8) | -2.31 (0.41) | Not mentioned | Not mentioned | Not mentioned | Not mentioned | |||
| Mochizuki 2022 | Level III | Denosumab | 25 | 72.6 (7.1) | Not mentioned | Not mentioned | -1.8 (1.1) | -2.1 (0.4) | -2.6 (0.5) | 34.3 (20.0) | 360.1 (147.8) | |
| Romosozumab | 25 | 74.7 (7.9) | Not mentioned | Not mentioned | -2.0 (1.4) | -2.0 (1.4) | -3.0 (0.7) | 41.4 (24.6) | 427.2 (177.7) | |||